JP7580918B2 - Ｐ２ｙ１２受容体アンタゴニストの皮下投与 - Google Patents

Ｐ２ｙ１２受容体アンタゴニストの皮下投与 Download PDF

Info

Publication number
JP7580918B2
JP7580918B2 JP2019549420A JP2019549420A JP7580918B2 JP 7580918 B2 JP7580918 B2 JP 7580918B2 JP 2019549420 A JP2019549420 A JP 2019549420A JP 2019549420 A JP2019549420 A JP 2019549420A JP 7580918 B2 JP7580918 B2 JP 7580918B2
Authority
JP
Japan
Prior art keywords
receptor antagonist
administered
pharma
acceptable salt
ceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019549420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510043A (ja
JP2020510043A5 (https=
Inventor
バウマン マルティーヌ
クラムベルク マルクス
レイ マルクス
リーダラー マルクス
ルー セバスチャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of JP2020510043A publication Critical patent/JP2020510043A/ja
Publication of JP2020510043A5 publication Critical patent/JP2020510043A5/ja
Priority to JP2023008155A priority Critical patent/JP2023052576A/ja
Application granted granted Critical
Publication of JP7580918B2 publication Critical patent/JP7580918B2/ja
Priority to JP2024230902A priority patent/JP2025060907A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019549420A 2017-03-15 2018-03-14 Ｐ２ｙ１２受容体アンタゴニストの皮下投与 Active JP7580918B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023008155A JP2023052576A (ja) 2017-03-15 2023-01-23 Ｐ２ｙ１２受容体アンタゴニストの皮下投与
JP2024230902A JP2025060907A (ja) 2017-03-15 2024-12-26 Ｐ２ｙ１２受容体アンタゴニストの皮下投与

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2017/056175 2017-03-15
EP2017056175 2017-03-15
PCT/EP2018/056372 WO2018167139A1 (en) 2017-03-15 2018-03-14 Subcutaneous administration of a p2y12 receptor antagonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023008155A Division JP2023052576A (ja) 2017-03-15 2023-01-23 Ｐ２ｙ１２受容体アンタゴニストの皮下投与

Publications (3)

Publication Number Publication Date
JP2020510043A JP2020510043A (ja) 2020-04-02
JP2020510043A5 JP2020510043A5 (https=) 2021-04-22
JP7580918B2 true JP7580918B2 (ja) 2024-11-12

Family

ID=61899166

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019549420A Active JP7580918B2 (ja) 2017-03-15 2018-03-14 Ｐ２ｙ１２受容体アンタゴニストの皮下投与
JP2023008155A Pending JP2023052576A (ja) 2017-03-15 2023-01-23 Ｐ２ｙ１２受容体アンタゴニストの皮下投与
JP2024230902A Pending JP2025060907A (ja) 2017-03-15 2024-12-26 Ｐ２ｙ１２受容体アンタゴニストの皮下投与

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023008155A Pending JP2023052576A (ja) 2017-03-15 2023-01-23 Ｐ２ｙ１２受容体アンタゴニストの皮下投与
JP2024230902A Pending JP2025060907A (ja) 2017-03-15 2024-12-26 Ｐ２ｙ１２受容体アンタゴニストの皮下投与

Country Status (18)

Country Link
US (1) US11179390B2 (https=)
EP (1) EP3595666A1 (https=)
JP (3) JP7580918B2 (https=)
KR (1) KR102510832B1 (https=)
CN (1) CN110381947A (https=)
AU (1) AU2018234056B2 (https=)
BR (1) BR112019014567A2 (https=)
CL (1) CL2019002318A1 (https=)
EA (1) EA201992123A1 (https=)
IL (1) IL269286B2 (https=)
MA (1) MA49887A (https=)
MX (1) MX393334B (https=)
MY (1) MY205605A (https=)
PH (1) PH12019502111A1 (https=)
SG (1) SG11201908128YA (https=)
TW (1) TWI765002B (https=)
UA (1) UA125531C2 (https=)
WO (1) WO2018167139A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025060907A (ja) * 2017-03-15 2025-04-10 イドルシア・ファーマシューティカルズ・リミテッド Ｐ２ｙ１２受容体アンタゴニストの皮下投与

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3515924B1 (en) 2016-09-22 2021-12-15 Idorsia Pharmaceuticals Ltd Crystalline forms
SMT202600015T1 (it) 2020-07-15 2026-03-09 Viatris Asia Pacific Pte Ltd Composizione farmaceutica acquosa comprendente un antagonista del recettore p2y12
MX2024000653A (es) 2021-07-13 2024-01-31 Idorsia Pharmaceuticals Ltd Un proceso para la sintesis de ester de butilo de acido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidin-1-il)-2-fenil-pirimidin-4-c arbonil]-amino}-3-fosfono-propionil)-piperazin-1-carboxilico.
US20250197904A1 (en) 2022-03-14 2025-06-19 Viatris Asia Pacific Pte. Ltd. A process for the synthesis of ( r)-2-(( tert-butoxycarbonyl)amino)-3-(diethoxyphosphoryl)propanoic acid or of phosphonate derivatives thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007506661A (ja) 2003-06-24 2007-03-22 アクテリオン　ファマシューティカルズ　リミテッド ピラゾリジンジオン誘導体
WO2011137459A1 (en) 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870035A (en) 1970-07-17 1975-03-11 Survival Technology Method and apparatus for self-administering pre-hospital phase treatment of coronary prone individuals in the early minutes or hours after the onset of heart attack symptoms
US4004577A (en) 1972-12-04 1977-01-25 Survival Technology, Inc. Method of treating heart attack patients prior to the establishment of qualified direct contact personal care
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
US4795433A (en) 1985-05-20 1989-01-03 Survival Technology, Inc. Automatic injector for emergency treatment
US4658830A (en) 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
US5078680A (en) 1984-08-08 1992-01-07 Survival Technology, Inc. Automatic injector for emergency treatment
GR861289B (en) 1985-05-20 1986-09-16 Survival Technology Injection method and apparatus with electrical blood absorbing stimulation
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
JP2003502314A (ja) 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
DE60333866D1 (de) 2002-12-11 2010-09-30 Bayer Schering Pharma Ag 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten
ATE481103T1 (de) 2003-04-09 2010-10-15 Wyeth Llc Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
AU2006305538B2 (en) 2005-10-21 2012-06-28 Idorsia Pharmaceuticals Ltd Piperazine derivatives as antimalarial agents
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
MX2009011089A (es) 2007-04-23 2009-10-30 Sanofi Aventis Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
CA2686203A1 (en) 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
EP2225253B1 (en) 2007-11-29 2012-06-27 Actelion Pharmaceuticals Ltd. Phosphonic acid derivates and their use as p2y12 receptor antagonists
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
MA33260B1 (fr) 2009-04-08 2012-05-02 Actelion Pharmaceuticals Ltd 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines
CA2756654C (en) 2009-04-22 2017-08-22 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists
WO2011160768A1 (en) 2010-06-23 2011-12-29 Stefan Kralev Medical device for self-administration of patients with acute coronary events
EP3515924B1 (en) 2016-09-22 2021-12-15 Idorsia Pharmaceuticals Ltd Crystalline forms
MA49887A (fr) * 2017-03-15 2020-06-24 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007506661A (ja) 2003-06-24 2007-03-22 アクテリオン　ファマシューティカルズ　リミテッド ピラゾリジンジオン誘導体
WO2011137459A1 (en) 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｃｌｉｎ Ｄｒｕｇ Ｉｎｖｅｓｔｉｇ，２０１４年，Ｖｏｌ．３４，ｐ．８０７－８１８
Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ，２０１５年，Ｖｏｌ．５８，ｐ．９１３３－９１５３

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025060907A (ja) * 2017-03-15 2025-04-10 イドルシア・ファーマシューティカルズ・リミテッド Ｐ２ｙ１２受容体アンタゴニストの皮下投与

Also Published As

Publication number Publication date
AU2018234056A1 (en) 2019-10-31
TW201840323A (zh) 2018-11-16
SG11201908128YA (en) 2019-10-30
EP3595666A1 (en) 2020-01-22
EA201992123A1 (ru) 2020-02-25
IL269286B1 (en) 2023-04-01
JP2020510043A (ja) 2020-04-02
BR112019014567A2 (pt) 2020-02-18
US11179390B2 (en) 2021-11-23
TWI765002B (zh) 2022-05-21
PH12019502111A1 (en) 2020-03-16
CN110381947A (zh) 2019-10-25
WO2018167139A1 (en) 2018-09-20
IL269286B2 (en) 2023-08-01
KR102510832B1 (ko) 2023-03-15
US20200129510A1 (en) 2020-04-30
IL269286A (en) 2019-11-28
MA49887A (fr) 2020-06-24
KR20190124297A (ko) 2019-11-04
CL2019002318A1 (es) 2020-01-10
UA125531C2 (uk) 2022-04-13
JP2023052576A (ja) 2023-04-11
AU2018234056B2 (en) 2023-05-25
MY205605A (en) 2024-10-29
MX393334B (es) 2025-03-24
JP2025060907A (ja) 2025-04-10
CA3050831A1 (en) 2018-09-20
NZ757938A (en) 2024-07-05
MX2019009559A (es) 2019-10-15

Similar Documents

Publication Publication Date Title
JP2025060907A (ja) Ｐ２ｙ１２受容体アンタゴニストの皮下投与
US20180344682A1 (en) Compositions and methods for treating ischemic stroke
KR20220163986A (ko) 브루톤 티로신 키나아제의 억제제를 이용한 재발성 다발성 경화증의 치료 방법
AU2012254057B2 (en) Use of A2B adenosine receptor antagonists for treating heart failure and arrhythmia in post-myocardial infarction patients
Mansi et al. Dual antithrombotic therapy dose-dependently alters hemostatic plug structure and function
CA3050831C (en) Subcutaneous administration of a p2y12 receptor antagonist
TW202146022A (zh) 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法
JP7490881B2 (ja) Ｐ２ｙ１２受容体アンタゴニストを有する水性医薬組成物
EA042138B1 (ru) Подкожное введение антагониста p2y12 рецептора
US20230364007A1 (en) Administration of a psychedelic compound
JP2026512953A (ja) ４０～２４０ｍｇの用量で虚血性事象の治療に使用するための組換えアピラーゼタンパク質

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230123

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230123

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230131

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230207

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230331

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241030

R150 Certificate of patent or registration of utility model

Ref document number: 7580918

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150